1. Semaglutide supply resumption - Testing of semaglutide API finishes around the third week of September 2026, with 6-7 crore pens to be supplied between November and March against backed orders. This restores a franchise that lost 3-4 crore pens during the stoppage, with PLI benefits to follow once supply resumes.
2. Abatacept US launch - The FDA accepted the BLA in February 2026 with a mid-December 2026 goal date; no queries received as of the Q1 FY27 call. Launch at patent expiry early calendar 2027 makes biologics profitable from day one, with Europe IV and subcutaneous filings following.
3. Bosutinib exclusivity - First-to-market launch with 180-day generic exclusivity on the 400 mg strength, commercialized June 13, 2026, against a US$253.8 million brand. Two weeks of supply hit Q1; margins run above company average, with nintedanib and other complex launches following.
4. NRT integration completion - Integration reached \~95% by March 31, 2026, with direct distribution now in place. The business grew 8% constant currency in Q3 FY26, exceeding the single-digit model with EBITDA above the 25% business-case level.
5. India innovative portfolio - India grew 17% YoY in Q1 FY27 with 15.5% organic growth; toripalimab entered the ₹100 crore club in under two years. Five in-licensing deals signed in FY26, including picankibart and tegoprazan, support the stated path to #5 in the Indian market.
6. Emerging Markets scale - Emerging Markets grew 31% YoY in Q1 FY27 to ₹1,833 crore, 23% of revenue, with 43 new product launches. Russia alone grew 28% YoY in Q1, with cost growth in low single digits supporting margin expansion.
7. Denosumab Europe rollout - European Commission and UK MHRA approvals received; launched in Germany in December 2025 with UK and other European launches underway. This is the main pipeline launch for Europe, with the US CRL from partner Alvotech's facility expected to resolve in Q2 FY27.
8. CDMO scale-up - Aurigene served as exclusive API manufacturer for two of 46 FDA-approved novel drugs in 2025, with quarterly sales of \~$17-18 million. Management targets US$100+ million growth in 2-3 years from discovery programs and exclusive supply, toward US$250-300 million by 2030.
9. Cost productivity program - Management targets 500-600 bps of cost reduction, with sales growing double digits while costs grow low single digits. Capex guidance dropped to \~₹1,800 crore from ₹2,500-2,700 crore, freeing cash flow as the gap between revenue and cost growth widens.